Catalyst Event
Genmab A/S (GMAB) · Other
From KEDI Nvidia Fixed Tech100 Index (KNVDT100)
4/13/2026, 12:00:00 AM
Presented positive safety and tolerability data from the Phase 1/2 study of rinatabart sesutecan (Rina-S) in combination with bevacizumab for advanced ovarian cancer, with no new safety signals identified.
Korean Translation
진행성 난소암에 대한 리나타바트 세수테칸(Rina-S)과 베바시주맙 병용 요법의 1/2상 임상시험에서 새로운 안전성 신호 없이 긍정적인 안전성 및 내약성 데이터를 발표함.
Related Recent Events
Credo Technology Group Holding Ltd (CRDO) · Earnings Release
Q4 and Full Fiscal Year 2026 earnings release on 2026-06-01 expected. Analysts forecast EPS around $0.93 and revenue of approximately $431 million forecasted. Earnings releases typically cause 5-10% price movement.
6/1/2026, 12:00:00 AM
Marvell Technology Inc (MRVL) · Earnings Release
First quarter fiscal year 2027 earnings results are scheduled to be released on May 29, 2026. Market impact is estimated at >1% as earnings releases typically drive volatility scheduled.
5/29/2026, 12:00:00 AM
Analog Devices Inc (ADI) · Earnings Release
Analog Devices is expected to release its fiscal second quarter 2026 financial results around late May. The date is estimated based on previous reporting schedules and is scheduled.
5/28/2026, 12:00:00 AM
Axon Enterprise Inc (AXON) · Other
Axon's Annual Meeting of Shareholders on 2026-05-28 where director Matthew McBrady will not seek re-election, which is estimated to have low importance as board changes are common, is scheduled.
5/28/2026, 12:00:00 AM
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA Q1 FY2027 earnings release and conference call scheduled. Low importance is estimated as a date announcement typically has >=1% price impact.
5/27/2026, 12:00:00 AM
Synopsys Inc (SNPS) · Earnings Release
Low importance estimated as market impact is pending results; Q2 2026 earnings release is scheduled.
5/27/2026, 12:00:00 AM